Enhancing of anti-viral activity against HIV-1 by stimulation of CD8+ T cells with thymic peptides

Clinical and Experimental Immunology

Volumn 117, Issue 1, 1999, Pages 76-83

  Muller H ^a   Mayer, G ^b   Behnke, B ^b   Heimuller E ^b   Hamscher, G ^c   Immler, D ^c   Siethoff, C ^c   Meyer, H E ^c   Schreiber, Michael ^a  

^a BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^b Strathmann AG and Co   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Anti viral factors; CD8+ T cells; HIV 1; Thymic peptides

Indexed keywords

CHEMOKINE; HISTONE; INTERLEUKIN 2; PHYTOHEMAGGLUTININ; THYMUS PEPTIDE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CELL STIMULATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MONONUCLEAR CELL; PRIORITY JOURNAL; SEQUENCE ANALYSIS; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VIRUS NEUTRALIZATION;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINES, CXC; COLLAGEN; CULTURE MEDIA, CONDITIONED; GIANT CELLS; HISTONES; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKIN-2; MOLECULAR SEQUENCE DATA; PEPTIDES; PHYTOHEMAGGLUTININS; RANTES; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY, AMINO ACID; THYMUS GLAND; TISSUE EXTRACTS;

EID: 0033048572     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.00936.x     Document Type: Article

References (49)

1. Walker CM, Moody DJ, Stiles DP, Levy JA. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986; 234:1563-6.
2. Walker CM, Moody DJ, Stites DP, Levy JA. CD8+ T lymphocytes control of HIV replication in cultured CD4+ cells varies among infected individuals. Cell Immunol 1989; 119:470-5.
3. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270:1811-5.
4. Oberlin E, Amara A, Bachelerie F et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996; 382:833-5.
5. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, Springer TA. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996; 382:829-33.
6. Pal R, Garzino-Demo A, Markham PD, Burns J, Brown M, Gallo RC, DeVico AL. Inhibition of HIV-1 infection by the beta-chemokine MDC. Science 1997; 278:695-8.
7. Speck RF, Wehrly K, Platt EJ, Atchison RE, Charo II, Kabat D, Chesebro B, Goldsmith MA. Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol 1997; 71:7136-9.
8. Alkhatib G, Combadiere C, Broder CC et al. CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophagetropic HIV-1. Science 1996; 272:1955-8.
9. Feng Y, Broder CC, Kennedy PF, Berger EA, HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272:872-7.
10. Alkhatib G, Broder CC, Berger EA. Cell type-specific fusion cofactor; determine human immunodeficiency virus type 1 tropism for T-cell lines versus primary macrophages. J Virol 1996; 70:5487-94.
11. Berger EA, Doms RW, Penyo EM et al. A new classification for HIV-1. Nature 1998; 391:240.
12. Berson JF, Long D, Doranz BJ, Rucker J, Jirik FR, Doms RW. A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J Virol 1996; 70:6288-95.
13. Baier M, Bannert N, Werner A, Adler HS, Otteken A, Beer B, Norley S, Kurth R. Chemoattractant factors and the control of human immunodeficiency virus replication. Pathobiology 1998; 66:128-30.
14. Leith JG, Copeland KF, McKay PJ, Richards CD, Rosenthal KI. CD8+ T-cell-mediated suppression of HIV-1 long terminal repeat-driven gene expression is not modulated by the CC chemokines RANTES, macrophage inflammatory protein (MIP)-1 alpha and MIP-1 beta. AIDS 1997; 11:575-80.
15. Mackewicz CE, Blackbourn DJ, Levy JA. CD8+ T cells suppress human immunodeficicney virus replication by inhibiting viral transcription. Proc Natl Acad Sci USA 1995; 92:2308-12.
16. Mackewicz CE, Barker E, Levy JA. Role of beta-chemokines in suppressing HIV replication. Science 1996; 274:1393-5.
17. Brinchmann JE, Gaudernack G, Vartdal F. In vitro replication of HIV-1 in naturally infected CD4+ T cells is inhibited by rIFN alpha 2 and by a soluble factor secreted by activated CD8+ T cells, but not by rIFN beta, rIFN gamma, or recombinant tumor necrosis factor-alpha. J Acquir Immune Defic Syndr 1991; 4:480-8.
18. Moriuchi H, Moriuchi M, Combadiere C, Murphy PM, Fauci AS. CD8+ T-cell-derived soluble factor(s), but not beta-chemokines RANTES, MIP-1 alpha, and MIP-1 beta, suppress HIV-1 replication in monocyte/macrophages. Proc Natl Acad Sci USA 1996;93:15341-5.
19. Schmidtmayerova H, Sherry B, Bukrinsky M. Chemokines and HIV replication. Nature 1996;382:767.
20. Walker CM, Levy JA. A diffusible lymphokine produced by CD8+ T lymphocytes suppresses HIV replication. Immunol 1989; 66:628-30.
21. Mackewicz C, Levy JA. CD8+ cell anti-HIV activity: Nonlytic suppression of virus replication. AIDS Res Hum Retrovir 1992; 8:1039-50.
22. Hadden JW, Saha A, Sosa M, Hadden EM. Immunotherapy with natural interleukins and/or thymosin alpha 1 potently augments T-lymphocyteresponses of hydrocortisone-treated aged mice. Int J Immunopharmacol 1995; 17:821-8.
23. Birr C, Bohn B, Jaeger KH. Biochemical characterization and immunomodulatory action of thymic components as determined by flow cytometry on human lymphocytes. Thymus 1987; 10:159-68.
24. Schreiber M, Petersen H, Watchsmuth C, Müller H, Hufert FT, Schmitz H. Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum. J Virol 1994; 68:3908-16.
25. Nakayama EE, Shioda T, Tatsumi M et al. Importance of the N-glycan in the V3 loop of HIV-1 envelope protein for CXCR-4- but not CCR-5-dependent fusion. FEBS Letters 1998; 426:367-72.
26. Moore JP, McKeating JA, Weiss RA, Sattentau QJ. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 1990; 250:1139-42.
27. Riviere, Y, Tanneau-Salvadori F, Regnault A et al. Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: Distinct types of effector cells mediate killing of targets expressing gag and env proteins. J Virol 1998; 63:2270-7.
28. Toda S, Ishii N, Okada E et al. HIV-1-specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannancoated liposomes and inhibited by anti-interferon-gamma antibody. Immunology 1997; 92:111-7.
29. Thomson SA, Sherritt MA, Medveczky J, Elliott SL, Moss DJ, Fernando GJ, Brown LE, Suhrbier A. Delivery of multiple CD8 cytotoxic T cell epilopes by DNA vaccination. J Immunol 1998; 160:1717 23.
30. Khatri VP, Baiocchi PA, Bernstein ZP, Caligiuri MA. Immunotherapy with low-dose interleukin-2: Rationale for prevention of immune-deficiency-associated cancer. Cancer J Sci Am 1997; 1:S129-S36.
31. Jacobson EL, Pilaro F, Smith KA. Rational interleukin 2 therapy for HIV positive individuals: Daily low doses enhance immune function without toxicity. Proc Natl Acad Sci USA 1996; 93:1040-10.
32. Landay AL, Clerici M, Hashemi F, Kessler H, Berzofsky JA, Shearer GM. In vitro restoration cell immune function in human immunodeficiency virus-positive persons: Effects or interleukin (IL)-12 and anti-IL-10. J Infect Dis 1996; 173:1085-91.
33. Valesini G, Barnaba V, Benvenuto R, Balsano F, Mazzanti P, Cazzola P. A calf thymus acid lysate improves clinical symptoms and T-cell defects in the early stages of HIV infection: Second report. Eur J Cancer Clin Oncol 1987; 23:1915-9.
34. Garaci E, Mastino A, Favalli C. Enhanced immune response and antitumor immunity with combinations of biological response modifiers. Bull N Y Acad Med 1989; 65:111-9.
35. Maggiolo F, Taras A, Pravettoni MG, Leone M, Ingrosso A, Suter F. Zidovudine and thymus humoral factor gamma-2 in the treatment of HIV infection: Preliminary clinical experience. Infection 1997; 25:35-38.
36. Mascart-Lemone F, Huygen K, Clumeck N, Brenez D, Bolla K, Duchateau J. Stimulation of cellular function by thymopentin (TP-5) in three AIDS patients. Lancet 1983; 24:735-6.
37. Rosok B, Voltersvik P, Larsson BM, Albert J, Brinchmann JE, Asjo B. CD8+ T cells from HIV type 1-seronegative individuals suppress virus replication in acutely infected cells. AIDS Res Hum Retrovir 1997; 13:79-85.
38. Clerici M, Balotta C, Trabattoni D et al. Chemokine production in HIV-seropositive long-term asymptomatic individuals. AIDS 1996; 10:1432-3.
39. Geretti AM, Dings ME, van Els CA, van Baalen CA, Wijnholds FJ, Borleffs JC, Osterhaus AD. Human immunodeficiency virus type 1 (HIV-1) and Epstein-Barr virus-specific cytotoxic T lymphocyte precursors exhibit different kinetics in HIV-1-infected persons. J Infect Dis 1996; 174:34-45.
40. Moore JP, Cao Y, Qing L et al. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp 120, and their neutralization is not predicted by studies with monomeric gp 120. J Virol 1995; 69:101-9.
41. Bazan HA, Alkhatib G, Broder CC, Berger EA. Patterns of CCR5, CXCR4, and CCR3 usage by envelope glycoproteins from human immunodeficiency virus type 1 primary isolates. J Virol 1998; 72:4485-91.
42. Hadden JW. T-cell adjuvants. Int J Immunopharmacol 1994; 16:703-10.
43. Costigliola P, Ricchi E, Colangeli V, Pintori C, Boni P, Chiodo F. Thymopentin (TP-5) therapy during lymphadenopathy syndrome (LAS/ARC): Preliminary report. J Exp Pathol 1987;3:705-12.
44. Clumeck N, Cran S, Van de Perre P, Mascart-Lemone F, Duchaleau J, Bolla K. Thymopentin treatment in AIDS and pre-AIDS patients. Surv Immunol Res 1985; 4:58-62.
45. Glushakova S, Grivel JC, Fitzgerald W, Sylwester A, Zimmerberg J, Margolis LB. Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency. Nat Med 1998; 4:346-9.
46. Müller P, Engelstadter M, Werner A et al. Increased serum and mRNA levels of RANTES associated with elevated levels of activated CD8+ CD38+ T cells in HIV-1 infected individuals. Intervirology 1997; 40:263-70.
47. Zerhouni B, Sanhadji K, Touraine JL. Loss of T-cell cytotoxic responses in the course of HIV-1 infection. Thymus 1997; 24:203 19.
48. Ferbas J. Perspectives on the role of CD8+ cell suppressor factors and cytotoxic T lymphocytes during HIV infection. AIDS Res Hum Retrovir 1998; 14:S153-S60.
49. Altschul SF, Madden TI, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. Nucleic Acids Res 1997; 25:3389-402.